| product_name | (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride |
| CAS_number | 159209-62-2 |
| formula | C13H12N2O2·HCl |
| molar_mass | 280.71 g/mol |
| property_1 | Solid form |
| property_2 | Off-white color |
| property_3 | Solubility in water: slightly soluble |
| property_4 | Melting point: not specified |
| property_5 | Boiling point: not specified |
| property_6 | Storage conditions: room temperature |
| property_7 | Use in chemical synthesis |
| property_8 | Used in pharmaceutical applications |
| property_9 | Stable under recommended storage conditions |
| property_10 | Sensitive to moisture |
What is the role of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride
(1:1) in pharmaceuticals?
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid
hydrochloride (1:1) is a compound that has shown promising results in the field of
pharmaceutical research. It has been found to have potential therapeutic effects in treating
various medical conditions due to its unique chemical structure and properties. This
compound has the ability to interact with specific biological targets in the body, making it
a valuable tool for developing new medications.
How does
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) work at the
molecular level?
The molecular structure of
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) allows it to bind
to certain receptors or enzymes in the body, modulating their activity and influencing
biological processes. This interaction can lead to a variety of effects, such as altering
signaling pathways, regulating gene expression, or inhibiting the function of specific
proteins involved in disease pathways. By understanding how this compound works at the
molecular level, researchers can better design drugs that target specific mechanisms of
action.
What are the potential therapeutic applications of
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1)?
The
therapeutic potential of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride
(1:1) lies in its ability to target specific pathways or processes that are implicated in
various diseases. This compound has shown promise in the treatment of conditions such as
cancer, inflammatory disorders, neurodegenerative diseases, and metabolic disorders. By
harnessing the unique properties of this molecule, researchers hope to develop new and more
effective treatments for these challenging medical conditions.
What are the benefits
of using (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in drug
discovery?
The use of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid
hydrochloride (1:1) in drug discovery offers several advantages. This compound has a
well-defined structure, making it easier to study its interactions with biological targets
and predict its effects in the body. In addition, its chemical properties can be modified to
enhance its efficacy, selectivity, and safety profile. By including this compound in the
drug discovery process, researchers have access to a powerful tool for identifying new
therapeutic agents and improving existing medications.
Can
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) be used in
combination therapies?
Combination therapy, which involves using multiple drugs
simultaneously to target different aspects of a disease, is a common approach in modern
medicine. (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) can be a
valuable component of combination therapies, as it can complement the effects of other drugs
and enhance their overall efficacy. By combining this compound with other medications that
have complementary mechanisms of action, researchers can potentially achieve synergistic
effects and improve treatment outcomes for patients.
What are the challenges
associated with using (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride
(1:1) in pharmaceutical development?
While
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) shows great
promise in pharmaceutical development, there are several challenges that researchers may
encounter. One challenge is optimizing the compound's pharmacokinetic properties, such as
its absorption, distribution, metabolism, and excretion in the body. Additionally, ensuring
the compound's selectivity for its intended target and minimizing off-target effects are
critical considerations in drug development. Overcoming these challenges requires extensive
research, testing, and collaboration among scientists and clinicians.
What are the
future prospects for (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride
(1:1) in the pharmaceutical industry?
The future of
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in the
pharmaceutical industry looks promising. With ongoing research and development efforts
focused on harnessing the compound's therapeutic potential, there is a strong possibility of
discovering new applications for this molecule in treating a wide range of medical
conditions. As our understanding of the compound's mechanisms of action continues to
improve, it is likely to become an essential tool in drug discovery and development, leading
to the creation of innovative medications that can benefit patients worldwide.
How
can researchers and pharmaceutical companies collaborate to maximize the impact of
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in
healthcare?
Collaboration between researchers and pharmaceutical companies is crucial
for maximizing the impact of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid
hydrochloride (1:1) in healthcare. By sharing knowledge, resources, and expertise,
scientists can accelerate the development of new medications that incorporate this compound
and bring them to market more efficiently. Collaborations also enable the pooling of data
from various studies, which can lead to new insights into the compound's mechanisms of
action and potential applications. Ultimately, by working together, researchers and
pharmaceutical companies can unlock the full therapeutic potential of
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) and improve
patient outcomes in the healthcare industry.
